Briumvi — Medical Mutual

Relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing remitting disease, active secondary progressive disease)

Initial criteria

Patient age ≥ 18 years; AND
Patient has a relapsing form of multiple sclerosis; AND
Patient has experienced inadequate efficacy or significant intolerance to one disease-modifying agent used for multiple sclerosis; AND
Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

Patient age ≥ 18 years; AND
Patient has a relapsing form of multiple sclerosis; AND
Patient meets one of the following: (1) experienced a beneficial clinical response when assessed by at least one objective measure (e.g., MRI, EDSS, NEDA-3/4, FSIQ-RMS, relapse reduction, functional testing, MSFC, attenuation of brain volume loss); OR (2) experienced stabilization, slowed progression, or improvement in at least one symptom (motor function, fatigue, vision, bowel/bladder, spasticity, walking/gait, pain/numbness/tingling); AND
Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

1 year